Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix (263855) in Pregnant Women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
- 20 Nov 2019 Primary endpoint has been met. (Immunogenicity with respect to components of the study vaccine, in cord blood sample), according to results published in the Vaccine.
- 20 Nov 2019 Results published in the Vaccine.
- 05 Dec 2017 Status changed from active, no longer recruiting to completed.